Stocks Health care HUMA
NASDAQ · Health careHumacyte, Inc. (HUMA)
Humacyte, Inc. brought in $2.1M of revenue over the twelve months to June 30, 2026, up 159.3% from a year earlier. It posted a net loss of $96.7M. In fiscal 2025 capital spending exceeded operating cash flow by $105.9M. At June 30, 2026 it held $79.9M in cash against $36.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Humacyte, Inc.
- Net worth
- Humacyte, Inc. has a market value (market cap) of $126.5M at the latest share price, and shareholders' equity of $31.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2M, with a net loss of $40.8M. Over the 12 months to June 30, 2026: revenue $2.1M, net loss $96.7M.
- Cash flow
- In fiscal 2025 operations used $105M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Humacyte, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Humacyte, Inc. does
Humacyte, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker HUMA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | -$40.8M | -$0.26 | -$105.9M |
| 2024 | $0 | -$148.7M | -$1.26 | -$99.7M |
| 2023 | n/a | -$110.8M | -$1.07 | -$75.6M |
| 2022 | n/a | -$12M | -$0.12 | -$72.2M |
| 2021 | n/a | -$26.5M | -$0.66 | -$81.4M |
| 2020 | n/a | -$66.5M | -$11.54 | -$55.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HUMA ranks in Health care
Latest SEC filings
What Humacyte, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Executive or director change8-KHumacyte appointed Scott Coward and Paul Kuznik to its Board of Directors.
- August 25, 2026Delisting notice 25-NSE
- August 18, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 35% to $406K versus the same quarter last year; diluted EPS -$0.16 versus -$0.24.
- August 12, 2026
- July 31, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 13, 2026Activist stake changed SCHEDULE 13D/A
- June 22, 2026Passive stake (5% or more) SCHEDULE 13G
- June 15, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Humacyte, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $30.4K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Jones Keith AnthonyDirector | Bought | 10,000 | $5.6K |
| August 20, 2026 | Jones Keith AnthonyDirector | Bought | 10,000 | $6.9K |
| August 17, 2026 | Jones Keith AnthonyDirector | Bought | 30,000 | $17.8K |
| May 19, 2026 | Sebelius KathleenDirector | Bought | 56,818 | $50K |
| May 18, 2026 | Constantino Michael T.Director | Bought | 11,000 | $9.8K |
| May 18, 2026 | Sander Dale A.CFO and Chief Corp. Dev. Off | Soldpre-planned (10b5-1) | 45,887 | $41.1K |
| May 18, 2026 | Parikh Shamik JChief Medical Officer | Soldpre-planned (10b5-1) | 45,887 | $41.1K |
| November 16, 2025 | Parikh Shamik JChief Medical Officer | Received as pay | 311,100 | - |
Who owns HUMA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
5 insiders reported holding 781,901 shares in total, about $355.9K at the last price.
| Holder | Shares |
|---|---|
| Parikh Shamik JChief Medical Officer | 272,713 |
| Sander Dale A.CFO and Chief Corp. Dev. Off | 267,213 |
| Sebelius KathleenDirector | 148,025 |
| Jones Keith AnthonyDirector | 50,000 |
| Constantino Michael T.Director | 43,950 |
Questions about HUMA
What does Humacyte, Inc. do?
Humacyte, Inc. is a company in the Health care sector, listed on NASDAQ as HUMA. Its shares trade on NASDAQ under the ticker HUMA.
What is Humacyte, Inc.'s net worth?
Humacyte, Inc. has a market value (market cap) of $126.5M at the latest share price, and shareholders' equity of $31.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Humacyte, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $96.7M on revenue of $2.1M.
How much revenue does Humacyte, Inc. make?
Over the twelve months to June 30, 2026 Humacyte, Inc. reported revenue of $2.1M. That is 159.3% more than a year earlier.
When did Humacyte, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 7, 2026.
When is Humacyte, Inc.'s next earnings report?
Humacyte, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HUMA with
Follow HUMA
Get an email when Humacyte, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Humacyte, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.